Medeskan unexpectedly announced a new bond program in the amount of ₽ 10 billion Medeskan clinic chain did not reach the promised autumn issue. But due to the need to close the liquidity gap, the company introduced a new bond program in the amount of ₽10 billion. However, the company already has an existing bond program in the amount of ₽100 billion and a bond debt of ₽6.5 billion, which will have to be paid by 2027. The sudden announcement of the new bond program may also be related to the gradual exit from the business of the network of partner clinics in the form of Rostom - the state corporation reduced its share from 50% to 45.1%. The presence of the state corporation provides Mescan with a high ruA credit rating from the ACRA and Expert RA agencies, as well as investor confidence, although legally the state corporation does not provide bonds to the clinic chain. Without Rosatom, Medscan's own rating is lower, at ruBBB+. At the same time, Medscan's founder, Yevgeny Togolukov, continues to state publicly that the state corporation's share is still 50%. The new bond program was also announced against the backdrop of a continuing wave of bond defaults in the Russian market. Medscan is one of the most likely candidates for a default, which could become as significant as the recent case of Eurotrans - a default will be announced by a company in the medical sector, which has always been considered stable on the stock market.

Medeskan unexpectedly announced a new bond program in the amount of ₽ 10 billion Medeskan clinic chain did not reach the promised autumn issue. But due to the need to close the liquidity gap, the company introduced a new bond program in the amount of ₽10 billion. However, the company already has an existing bond program in the amount of ₽100 billion and a bond debt of ₽6.5 billion, which will have to be paid by 2027. The sudden announcement of the new bond program may also be related to the gradual exit from the business of the network of partner clinics in the form of Rostom - the state corporation reduced its share from 50% to 45.1%. The presence of the state corporation provides Mescan with a high ruA credit rating from the ACRA and Expert RA agencies, as well as investor confidence, although legally the state corporation does not provide bonds to the clinic chain. Without Rosatom, Medscan's own rating is lower, at ruBBB+. At the same time, Medscan's founder, Yevgeny Togolukov, continues to state publicly that the state corporation's share is still 50%. The new bond program was also announced against the backdrop of a continuing wave of bond defaults in the Russian market. Medscan is one of the most likely candidates for a default, which could become as significant as the recent case of Eurotrans - a default will be announced by a company in the medical sector, which has always been considered stable on the stock market.